MAXCYTE, INC.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

MXCT$1.30+3.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)


· Three Months Ended June 30, · · Six Months Ended June 30,
· · 2025 · 2024 · 2025 · 2024
Revenue	$8,507	$10,429	$18,897	$21,770
Cost of goods sold	1,519	1,488	3,016	2,891
Gross profit	6,988	8,941	15,881	18,879

Operating expenses:
Research and development	6,269	5,619	12,172	12,297
Sales and marketing	5,786	6,617	11,484	13,981
General and administrative	8,080	7,639	16,606	14,742
Depreciation and amortization	1,080	1,034	2,141	2,102
Total operating expenses	21,215	20,909	42,403	43,122
Operating loss	(14,227)	(11,968)	(26,522)	(24,243)

Other income:
Interest income	1,870	2,593	3,904	5,342
Total other income	1,870	2,593	3,904	5,342
Loss before income taxes	(12,357)	(9,375)	(22,618)	(18,901)
Provision for income taxes	—	—	—	—
Net loss	$(12,357)	$(9,375)	$(22,618)	$(18,901)
Basic and diluted net loss per share	$(0.12)	$(0.09)	$(0.21)	$(0.18)
Weighted-average shares outstanding, basic and diluted	106,403,540	104,639,239	106,178,262	104,364,498

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.